ERGO.L - Ergomed plc

LSE - LSE Delayed price. Currency in GBp
480.00
-2.00 (-0.41%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous close482.00
Open490.00
Bid0.00 x 0
Ask0.00 x 0
Day's range470.00 - 490.00
52-week range258.00 - 635.00
Volume41,929
Avg. volume78,853
Market cap231.396M
Beta (5Y monthly)0.24
PE ratio (TTM)41.74
EPS (TTM)11.50
Earnings date25 Mar 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est265.41
  • Could Ergomed (LON:ERGO) be a turtle trade?
    Stockopedia

    Could Ergomed (LON:ERGO) be a turtle trade?

    Ever since the 1980s, when the now-infamous quot;Turtle Tradersquot; beat the market with simple strategies based on breakouts to new high prices, momentum i...

  • Globe Newswire

    Annual General Meeting Statement

    PRESS RELEASEAnnual General Meeting StatementGuildford, UK – 10 June 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the following update from Dr Miroslav Reljanović, Executive Chairman, in advance of the Company’s closed Annual General Meeting (‘AGM’) to be held this morning at 9.30am: “Ergomed had a good first quarter, with solid overall growth in revenue. Following the outbreak of COVID-19 in March 2020, the Company has successfully transferred to a fully remote working operation with minimal disruption and no redundancies or furloughed staff. “The Company has continued to make good strategic progress this year, with further integration of the combined business under the pharmaceutical services model. The Ashfield Pharmacovigilance business, acquired in January 2020, has been integrated in line with plans as PrimeVigilance USA, providing significant commercial benefit to the group overall. Cash generation remains strong, and the Company is in a robust financial position. “Despite the impact of COVID-19 on the general business environment, in the second quarter of 2020 the Company has continued to grow its order book across the business and to maintain its revenue growth trend whilst implementing effective cost control measures. The Company is confident in the performance of the business for the first half of 2020. “In line with our usual practice, in July 2020 the Company will provide an update on current trading and the outlook for the remainder of the current financial year ending 31 December 2020. At this time the Company is confident that results will be in line with current market expectations for the 2020 financial year. “Finally, on behalf of the Board, I would like to thank all of the Company’s colleagues and shareholders for their continuing support during the current challenging times.” The results of shareholder voting on the AGM resolutions will be announced following the conclusion of the meeting. ENDS Enquiries:Ergomed plc Tel: +44 (0) 1483 402 975 Miroslav Reljanović (Executive Chairman)  Richard Barfield (Chief Financial Officer)     Numis Securities LimitedTel: +44 (0) 20 7260 1000 Freddie Barnfield / Huw Jeremy (Nominated Adviser)  James Black (Broker)     Consilium Strategic Communications – for UK enquiriesTel: +44 (0) 20 3709 5700 Chris Gardner / Sue Stuartergomed@consilium-comms.com Matthew Neal / Olivia Manser     About Ergomed plcErgomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

  • Why having a high ROE helps shareholders of Ergomed
    Stockopedia

    Why having a high ROE helps shareholders of Ergomed

    Return on equity (ROE) measures how efficiently a company uses Shareholders’ Equity to generate profits. For any readers unfamiliar with ROE, it is calculated...

  • Globe Newswire

    Ergomed to Present at Jefferies Virtual 2020 Healthcare Conference

    PRESS RELEASEErgomed to Present at Jefferies Virtual 2020 Healthcare ConferenceGuildford, UK – 28 May 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces that Richard Barfield, Chief Financial Officer of Ergomed, will present at the Jefferies Virtual Healthcare Conference at 2pm BST on 2 June 2020.A live webcast of the presentation will be available on Ergomed’s website, here: https://www.ergomedplc.com/investor-relations/reports-and-presentations/ENDSEnquiries:Ergomed plc Tel: +44 (0) 1483 402 975 Miroslav Reljanović (Executive Chairman)  Richard Barfield (Chief Financial Officer)     Numis Securities LimitedTel: +44 (0) 20 7260 1000 Freddie Barnfield / Huw Jeremy (Nominated Adviser)  James Black (Broker)     Consilium Strategic Communications – for UK enquiriesTel: +44 (0) 20 3709 5700 Chris Gardner / Sue Stuartergomed@consilium-comms.com Matthew Neal / Olivia Manser     About Ergomed plcErgomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

  • Globe Newswire

    Ergomed Enters Strategic Collaboration to Drive Pharmacovigilance Leadership in Intelligent Automation

    RNS REACH PRESS RELEASEErgomed Enters Strategic Collaboration to Drive Pharmacovigilance Leadership in Intelligent Automation PrimeVigilance collaboration with Automation Anywhere and DataRobot to advance robotic processes and machine learning Guildford, UK – 18 May 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce PrimeVigilance’s strategic collaboration with Automation Anywhere, a global leader in Robotic Process Automation (RPA) and DataRobot, the leader in enterprise artificial intelligence (AI), to accelerate the Company’s Intelligent Automation strategy.PrimeVigilance, a division of Ergomed, is the leading global specialized provider of full pharmacovigilance (PV) services, and currently employs over 750 people. By empowering its clients and colleagues with the application of RPA and Machine Learning (ML), PrimeVigilance will enable clients to improve quality and consistency within safety databases, as well as productivity.A successful proof of concept has been completed, and PrimeVigilance will now implement a cloud software solution to automate specific pharmacovigilance processes. The productivity gains made possible by working with Automation Anywhere and DataRobot, are expected to deliver organic growth more efficiently, with the automation of manual, repetitive processes. Automation Anywhere’s cloud-based RPA on its digital workforce platform combined with DataRobot’s enterprise AI platform will bring new levels of speed and intelligence to a crucial component of the business, freeing up valuable hours for highly trained pharmacovigilance professionals to focus on value creation and problem solving that only humans can address.This strategic partnership will be part of Ergomed’s wider strategy as it transforms the relationship between its people and technology, enhancing the Company’s creativity, agility and skills for the benefit of its clients and shareholders. It will enhance Ergomed’s existing skills and expertise by combining human insight and knowledge with the intelligent application of technology to enhance the speed and precision of analysis and decision making.Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “Adoption of the latest available technologies, including automation and robotic technology across our pharmacovigilance business, ensures we are able to continue to offer cutting edge services to our customers. This collaboration provides the foundation to rapidly identify and automate a wide range of business processes, enabling clients to maximise quality and consistency within safety databases as well as increasing productivity.”Prince Kohli, Chief Technology Officer at Automation Anywhere, commented: "Intelligent Automation can help to unlock valuable human capacity to focus on innovation-led projects, while reducing costs and shortening the time to market. Ergomed understands this opportunity, and we're excited to be working with them and DataRobot to unleash the potential of Intelligent Automation to enable a better customer experience and faster time to value.” Automation Anywhere Enterprise A2019, was designed from the ground up as a cloud-native and web-based RPA platform offering lower total cost of ownership (TCO), increased performance and scalability. It combines advanced RPA, artificial intelligence (AI) and embedded analytics, enabling enterprises to digitize business operations, driving scalability, reusability and lowering operating costs. The company’s software bots, which are delivered via the cloud, work side-by-side with human workers to automate repetitive, mundane tasks, freeing up valuable human resources to focus on more meaningful work.“Companies across all sectors and geographies have learned that they can transform their business by embracing Intelligent Automation,” said Dan Wright, President and COO, DataRobot. “By implementing this technology, companies can combine the best of human and machine intelligence, drive rapid automation and enhanced operational efficiency, and experience exponential returns on their investment. We’re excited to have teamed up with Automation Anywhere to help Ergomed push the boundaries of what’s possible.”DataRobot is the leader in enterprise AI, delivering trusted AI technology and return on investment (ROI) enablement services to global enterprises competing in today’s Intelligence Revolution. DataRobot’s enterprise AI platform democratizes data science with end-to-end automation for building, deploying, and managing machine learning models.ENDSEnquiries:Ergomed plc Tel: +44 (0) 1483 402 975 Miroslav Reljanović (Executive Chairman)  Richard Barfield (Chief Financial Officer)     Numis Securities LimitedTel: +44 (0) 20 7260 1000 Freddie Barnfield / Huw Jeremy (Nominated Adviser)  James Black (Broker)     Consilium Strategic Communications – for UK enquiriesTel: +44 (0) 20 3709 5700 Chris Gardner / Sue Stuartergomed@consilium-comms.com Matthew Neal / Olivia Manser     Automation Anywhere Tel: +44 79 32552473 Kerry DavisKerry.davis@automationanywhere.com    DataRobotTel: +1-617-765-4500 Libby BotsfordElizabeth.botsford@datarobot.com    About Ergomed plcErgomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.About Automation Anywhere Automation Anywhere is a global leader in Robotic Process Automation (RPA), empowering customers to automate end-to-end business processes with software bots – digital workers that perform repetitive and manual tasks, resulting in dramatic productivity gains, optimized customer experience and more engaged employees. The company offers the world’s only web-based and cloud-native intelligent automation platform combining RPA, artificial intelligence, machine learning, and analytics right out of the box, to help organizations rapidly start and scale their process automation journey. Its Bot Store is the world's first and largest marketplace with more than 850 pre-built, intelligent automation solutions. With offices in more than 40 countries and a global network of 1,500 partners, Automation Anywhere has deployed over 1.8 million bots to support some of the world’s largest enterprises across all industries. For additional information, visit www.automationanywhere.com.About DataRobot DataRobot is the leader in enterprise AI, delivering trusted AI technology and enablement services to global enterprises competing in today’s Intelligence Revolution. DataRobot’s enterprise AI platform democratizes data science with end-to-end automation for building, deploying, and managing machine learning models. This platform maximizes business value by delivering AI at scale and continuously optimizing performance over time. The company’s proven combination of cutting-edge software and world-class AI implementation, training, and support services, empowers any organization – regardless of size, industry, or resources – to drive better business outcomes with AI.With a singular focus on AI since its inception, DataRobot has a proven track record of delivering AI with ROI. DataRobot has offices across the globe and $431 million in funding from top-tier firms, including New Enterprise Associates, Sapphire Ventures, Meritech, and DFJ Growth. For more information, visit https://www.datarobot.com, and join the conversation on Twitter and LinkedIn.

  • Globe Newswire

    Ergomed Announces Provision of Clinical Research Services for Second COVID-19 Clinical Development Programme

    PRESS RELEASEErgomed Announces Provision of Clinical Research Services for Second COVID-19 Clinical Development ProgrammeGuildford, UK – 6 April 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces it is providing support for a clinical development programme for namilumab, a monoclonal antibody therapy targeting granulocyte-macrophage colony stimulating factor (GM-CSF), for the treatment of patients with rapidly worsening COVID-19. The programme is being conducted at the Humanitas Research Hospitals in Bergamo and Milan, Italy and is supported by Izana Bioscience, an Oxford, UK-based biopharmaceutical company focused on the development of namilumab (see announcement below). Ergomed has been integrally involved in establishing the programme, drawing on its rapidly developing expertise in COVID-19, and the flexibility that underpins its specialist capabilities, including its unique site management model in successfully managing complex clinical programmes. Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “Research into potential treatments for COVID-19, and particularly the re-purposing of existing therapies and candidates, is imperative if the impact of the pandemic is to be reduced. We are currently providing clinical, operational and pharmacovigilance services to the re-purposing of three compounds for critically ill patients with COVID-19, demonstrating our ability to respond rapidly to customers’ needs at this time. As our experience with COVID-19 continues to build, we hope to bring our capabilities and expertise increasingly to bear on this fast moving and critically important field.” The full text of the announcement issued by Izana Bioscience on 6 April is as follows: Initiation of two-centre compassionate use study involving namilumab in the treatment of individual patients with rapidly worsening COVID-19 infection in Italy * Emergency access granted to investigational therapy * Objective to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation * Discussions with international regulators, KOLs and clinical centres of excellence are ongoing to progress namilumabOXFORD, England, April 06, 2020 – Izana Bioscience ("Izana" or "the Company"), the Oxford, UK-based biopharmaceutical company focused on the development of namilumab, today announces the initiation of a two-centre compassionate use study involving namilumab (IZN-101) in the treatment of patients with rapidly worsening COVID-19 in cooperation with the Humanitas research group, under the leadership of Professor Carlo Selmi, head of the Rheumatology and Clinical Immunology Unit at Humanitas Research Hospital and Associate Professor of Internal Medicine at Humanitas University. The study will take place in Bergamo and Milan, Italy.Namilumab is the Company’s wholly-owned, phase III-ready, fully human monoclonal antibody therapy targeting granulocyte-macrophage colony stimulating factor (GM-CSF), currently in late-stage clinical development for the treatment of rheumatoid arthritis and ankylosing spondylitis.GM-CSF is a pro-inflammatory cytokine that plays a central role in a broad range of immune-mediated diseases. The cytokine has been found in higher levels of COVID-19 ICU patients, according to recent data from China1 suggesting that early intervention could be beneficial in patients with rapidly worsening COVID-19.The compassionate use programme will gather data from hospitalised, rapidly worsening COVID-19 patients, and has the overall objective of treating them before they are admitted to intensive care or require ventilation.  It also aims to support namilumab’s future development for the treatment of COVID-19, and discussions with global regulatory authorities, including the UK, are in progress. Dr Someit Sidhu, Chief Executive and Co-founder of Izana Bioscience, said: “We are very pleased to be supporting this programme with our anti-GM-CSF mAb, namilumab, for the potential treatment of critically-ill COVID-19 patients. The role of GM-CSF in immune-mediated diseases is backed by a strong body of evidence and our growing understanding of COVID-19. Evidence suggests that anti GM-CSF therapy has the potential to change the way patients’ immune systems respond to the virus, and therefore to reduce dangerous inflammation and support recovery.” Professor Carlo Selmi, Coordinator of the study and Associate Professor of Internal Medicine at Humanitas University, said: “Clinicians working on the frontline urgently require new treatment options for their seriously ill COVID-19 patients. Anti-GM-CSF therapies such as namilumab could play an important role in how we can prevent or reduce the deterioration in COVID-19 patients for which there are currently few treatments available. I am convinced that, even in complicated scenarios such as the current one, it is mandatory to maintain a rigorous scientific approach and in this compassionate use programme we hope to identify patients with a higher inflammatory burden, those we believe are most likely to respond to anti GM-CSF therapy.”A number of patients are undergoing COVID-19 treatment at Humanitas and those that are eligible will be entered into the compassionate use programme with namilumab in accordance with local regulations. The team working with Prof. Selmi will be coordinated locally by Dr. Amidio Testa and Dr. Giacomo Guidelli.Drawing on its rapidly developing experience and expertise in the COVID-19 field, Ergomed plc, a CRO specialised in providing bespoke solutions and research services to the pharmaceutical industry, is facilitating this programme.About Izana Bioscience Izana is a translational medicine company focused on bringing innovative science to market. Izana was founded by a team of experienced pharmaceutical industry entrepreneurs and clinicians, led by Dr Someit Sidhu, Chief Executive of Izana Bioscience, and Chairman Professor Bryan Morton CBE. The Company has been initially focused on the development of namilumab in rheumatoid arthritis. Izana is backed by Innovate UK, and Takeda has a strategic equity stake in the Company.About namilumab (IZN-101) Namilumab is a human monoclonal antibody targeting granulocyte macrophage-colony stimulating factor (GM-CSF).  The antibody has demonstrated efficacy and safety in a phase IIb trial2 conducted in over 100 rheumatoid arthritis patients, and a phase II proof-of-concept study in ankylosing spondylitis is ongoing.References 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/s0140-6736(20)30183-5. 2. Taylor et al. Arthritis Research and Therapy (2019) 21:101      Enquiries:Ergomed plc Tel: +44 (0) 1483 402 975 Miroslav Reljanović (Executive Chairman)  Richard Barfield (Chief Financial Officer)     Numis Securities LimitedTel: +44 (0) 20 7260 1000 Freddie Barnfield / Huw Jeremy (Nominated Adviser)  James Black (Broker)     Consilium Strategic Communications – for UK enquiriesTel: +44 (0) 20 3709 5700 Chris Gardner / Sue Stuartergomed@consilium-comms.com Matthew Neal / Olivia Manser     About Ergomed plcErgomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

  • Earnings Update: Here's Why Analysts Just Lifted Their Ergomed plc (LON:ERGO) Price Target To UK£5.00
    Simply Wall St.

    Earnings Update: Here's Why Analysts Just Lifted Their Ergomed plc (LON:ERGO) Price Target To UK£5.00

    It's been a pretty great week for Ergomed plc (LON:ERGO) shareholders, with its shares surging 13% to UK£3.95 in the...

  • How Many Ergomed plc (LON:ERGO) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many Ergomed plc (LON:ERGO) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Is Ergomed (LON:ERGO) A Risky Investment?
    Simply Wall St.

    Is Ergomed (LON:ERGO) A Risky Investment?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Is Ergomed plc (LON:ERGO) Trading At A 21% Discount?
    Simply Wall St.

    Is Ergomed plc (LON:ERGO) Trading At A 21% Discount?

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Ergomed plc...

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more